I
nvestigational approaches with interferon-␥ (IFN-␥) in patients with metastatic melanoma have explored several routes of administration, from transduction of IFN-␥ gene into autologous harvested tumor tissue with reimplantation as a vaccine [1] [2] [3] to direct intratumoral injection 4, 5 of accessible lesions. From January 13, 1997 to August 18, 1997, 17 patients with metastatic melanoma were enrolled in a trial of a IFN-␥ retroviral vector 5 at May Crowley Medical Research Center in the Sammons Cancer Center at Baylor University Medical Center with US Oncology. The purpose of this study was to determine tolerability and evidence of immune reactivity to IFN-␥ retroviral vector (Chiron Corporation) after multiple intratumoral injections. Patients were divided into treatment arms that involve a single cycle of treatment (cohort A; n ϭ 9) and multiple 6 cycles of treatment (cohort B; n ϭ 8). Dose levels per cohort included 0.3, 0.5, or 1.0 ϫ 10 7 plaque-forming units/mL/day for 5 consecutive days every 2 weeks. All patients in cohort B either maintained stable disease (n ϭ 5) or achieved a partial or complete response (n ϭ 3) of the injected lesion, whereas in patients in cohort A, only 1 of 9 achieved a response. Initial assessment of cohort B confirmed safety and evidence of systemic and local immune reactivity. 5, 6 Now, after 2 years of follow-up, the median survival of cohort A is 150 days, compared with 369 days in cohort B (Fig 1) . In addition, analysis of follow-up blood samples for detection of replication-competent retrovirus as determined by polymerase chain reaction analysis for retroviral vector DNA 7 revealed no evidence of replication-competent retrovirus up to 6 months after treatment in 14 of the 16 patients analyzed. Two of 8 patients who received multiple injections were alive at last follow-up with stable disease, compared with 0 of 9 patients who received a single injection (longest survival was 426 days). In conclusion, long-term follow-up data suggest that multiple treatments with retroviral IFN-␥ gene are safe; in addition, preliminary evidence suggests that survival may be improved in correlation with immunoreactivity in patients receiving multiple injections. Further clinical investigation is recommended.
